

PRESS



For immediate release

EPIDAUROS Biotechnologie AG: Break even in 2003

April 22, 2004

Bernried, Germany - April 22, 2004 - EPIDAUROS Biotechnologie AG, a pharmacogenetics company located in Bernried near Munich, has reached break even in 2003 for the first time since the foundation of the company in 1997. After a restructuring of the company in November 2002, EPIDAUROS focused its business on pharmacogenetic services and consulting as well as pharmacogenetic research in collaborations with pharma companies and academic institutions. During fiscal year 2003 revenues have been moderately increased which together with a strict cost management contributed to the success of EPIDAUROS. The acceptance of EPIDAUROS' pharmacogenetic services and increased demand for these services lead to increased repeat business with existing customers and attracted new customers for the company. Currently the EPIDAUROS team is comprised of 26 employees. In the last year a renewal of the company's certification according to ISO 9001:2000 has been completed and for the first time the company successfully participated in proficiency testing. For the current year it is planned to achieve GLP certification.

Dr. Manfred Zoltbrocki, CEO of EPIDAUROS, anticipates a continued positive development of the pharmacogenetic business of the company and again he expects a positive result for EPIDAUROS in 2004.

Contact EPIDAUROS:

Dr. Manfred Zoltbrocki
EPIDAUROS Biotechnologie AG
CEO
Phone: ++49 (0)8158-9985-0
Fax: ++49 (0)8158-9985-48
Email: info@epidauros.com

PRESS



Company portrait of EPIDAUROS Biotechnologie AG

(www.epidauros.com)

EPIDAUROS Biotechnologie AG is a leading pharmacogenetics company that investigates the genetic factors influencing a person's response to a drug in order to make drug development and therapy safer and more efficient. Its aim is the "personalised drug" that is customised to the genetic profile of each patient. EPIDAUROS investigates and characterises variations of genes (polymorphisms) that encode for drug transporter proteins and for drug metabolising enzymes. In addition, EPIDAUROS investigates genes encoding drug targets.

EPIDAUROS offers pharmaceutical and biotechnology companies a comprehensive package of proprietary pharmacogenetic assays and services, which will significantly improve the results of clinical studies and drug treatment. EPIDAUROS develops profiling assays which help to pharmacogenetically characterise compounds in the pre-clinical phase of drug development and therefore to evaluate their success rate. Using EPIDAUROS' pharmacogenetic profiling assays, patients can be selected based on their genetic profiles during clinical phases. These tests minimise the possibility that a patient will receive an ineffective drug treatment or one that will cause adverse reactions.